Brief: Pci Biotech with Extension Of Preclinical Research Collaboration Agreement
June 15 (Reuters) - PCI Biotech Holding ASA PCIB.OL :
* REG-PCI BIOTECH: EXTENSION OF PRECLINICAL RESEARCH COLLABORATION AGREEMENT WITH A TOP-10
LARGE
PHARMA COMPANY
* EXTENDED EVALUATION PERIOD SPANS OVER 6 MONTHS, UNTIL END OF DECEMBER 2018, AND MAY BE
FURTHER
EXTENDED.
Source text for Eikon: ID:nGNE1Mhc3B
Further company coverage: PCIB.OL
(Gdynia Newsroom)
((Gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on PCI Biotech Holding ASA
See all newsBrief: Euronext Oslo Børs To Delist PCI Biotech Holding Shares
Brief: Euronext Oslo Børs Gets Application From PCI Biotech Holding For Delisting
Brief: PCI Biotech Holding Board Proposes Dissolution, Delisting
Brief: Oslo Bors: PCI Biotech Holding Is Placed In Recovery Box
Brief: PCI Biotech Says Co Initiates Process To Evaluate Opportunity For Structured Wind-Up Process